Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43933   clinical trials with a EudraCT protocol, of which   7307   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools

    < Back to search results

    Print Download

    EudraCT Number:2019-002550-23
    Sponsor's Protocol Code Number:HS0003
    National Competent Authority:Denmark - DHMA
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2020-03-27
    Trial results View results
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedDenmark - DHMA
    A.2EudraCT number2019-002550-23
    A.3Full title of the trial
    A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A Study to evaluate the efficacy and safety of bimekizumab in study participants with moderate to severe hidradenitis suppurativa
    A.3.2Name or abbreviated title of the trial where available
    A.4.1Sponsor's protocol code numberHS0003
    A.5.2US NCT (ClinicalTrials.gov registry) numberNCT04242446
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorUCB Biopharma SRL
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportUCB Biopharma SRL
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationUCB BIOSCIENCES GmbH
    B.5.2Functional name of contact pointClin Trial Reg & Results Disclosure
    B.5.3 Address:
    B.5.3.1Street AddressAlfred-Nobel-Strasse 10
    B.5.3.2Town/ cityMonheim
    B.5.3.3Post code40789
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameBimekizumab
    D.3.2Product code UCB4940
    D.3.4Pharmaceutical form Solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPSubcutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNBIMEKIZUMAB
    D.3.9.1CAS number 1418205-77-2
    D.3.9.2Current sponsor codeUCB4940
    D.3.9.4EV Substance CodeSUB182636
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number160
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D. cell therapy medicinal product No
    D. therapy medical product No
    D. Engineered Product No
    D. ATIMP (i.e. one involving a medical device) No
    D. on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboSolution for injection
    D.8.4Route of administration of the placeboSubcutaneous use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Hidradenitis Suppurativa
    E.1.1.1Medical condition in easily understood language
    Hidradenitis Suppurativa, a chronic skin disease that appears after puberty, may lead to painful nodules and scarring in armpits, groin and other areas. Nodules may rupture to form draining tunnels.
    E.1.1.2Therapeutic area Diseases [C] - Immune System Diseases [C20]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level LLT
    E.1.2Classification code 10020041
    E.1.2Term Hidradenitis suppurativa
    E.1.2System Organ Class 100000004858
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    Evaluate the efficacy of bimekizumab in study participants with moderate to severe Hidradenitis Suppurativa (HS)
    E.2.2Secondary objectives of the trial
    - Evaluate the efficacy of bimekizumab on other measures of disease activity in study participants with moderate to severe HS
    - Evaluate the safety of bimekizumab in study participants with moderate to severe HS
    E.2.3Trial contains a sub-study Yes
    E.2.3.1Full title, date and version of each sub-study and their related objectives
    Pharmacogenetics sub-study:
    For individuals consenting to the pharmacogenetic substudy, blood
    samples will be drawn for exploratory genetic/epigenetic analyses at
    specified timepoints. A separate ICF will be required for those study
    participants who agree to participate in the pharmacogenetics substudy.
    Refusal to participate in the substudy will not affect a study participant's
    ability to participate in the main study.
    Photography sub-study:
    At certain sites, where feasible, representative photographs of the
    changes in skin will be captured. Photographs will be anonymized. This
    is optional for study participants and requires a separate informed
    consent. A decision not to consent does not exclude the study participant
    from the study.
    E.3Principal inclusion criteria
    - Participant must be at least 18 years of age, at the time of signing the informed consent. If a study participant is under the local age of consent
    and is at least 18 years of age, written informed consent will be obtained
    from both the study participant and the legal representative
    - Study participants must have a diagnosis of Hidradenitis Suppurativa
    (HS) based on clinical history and physical examination for at least 6
    months prior to the Baseline visit; diagnosis must be verifiable through
    medical notes and documentation
    - Study participant must have HS lesions present in at least 2 distinct
    anatomic areas (eg, left and right axilla), 1 of which must be at least
    Hurley Stage II or Hurley Stage III at both the Screening and Baseline
    - Study participant must have moderate to severe HS defined as a total
    of ≥5 inflammatory lesions (ie, number of abscesses plus number of
    inflammatory nodules) at both the Screening and Baseline visits
    - Study participant must have had a history of inadequate response to a
    course of a systemic antibiotics for treatment of HS at the Screening
    Visit as assessed by the Investigator through study participant interview
    and review of medical history; inadequate response must be
    verifiable through medical notes and documentation
    - A female study participant is eligible to participate if she is not
    pregnant, not breastfeeding, and at least one of the following conditions
    a) Not a woman of childbearing potential (WOCBP)
    b) A WOCBP who agrees to follow the contraceptive guidance during the
    treatment period and for at least 20 weeks
    E.4Principal exclusion criteria
    Draining tunnel count of >20 at the Baseline Visit
    - Any other active skin disease or condition (eg, bacterial cellulitis,
    candida intertrigo, extensive condyloma) that may, in the opinion of the
    Investigator, interfere with the assessment of hidradenitis suppurativa
    - Study participant has a diagnosis of sarcoidosis, systemic lupus
    erythematosus, or active inflammatory bowel disease (IBD)
    - Primary immunosuppressive condition, including taking
    immunosuppressive therapy following an organ transplant, or has had a
    - Female who is breastfeeding, pregnant, or plans to become pregnant
    during the study or within 20 weeks following the final dose of
    investigational medicinal product (IMP)
    - Active infection or history of certain infection(s)
    - Active tuberculosis (TB) infection, latent TB infection, high risk of
    exposure to TB infection, current or history of nontuberculous
    mycobacterium (NTM) infection
    - Concurrent malignancy. Study participants with a history of malignancy
    within the past 5 years prior to the Screening Visit are excluded, EXCEPT
    if the malignancy was a cutaneous squamous or basal cell carcinoma, or
    in situ cervical cancer that has been treated and is considered cured
    - History of a lymphoproliferative disorder including lymphoma or
    current signs and symptoms suggestive of lymphoproliferative disease
    - Known hypersensitivity to any components of bimekizumab or
    comparative drugs as stated in this protocol
    - Concomitant and prior medication restrictions
    - Myocardial infarction or stroke within the 6 months prior to the
    Screening Visit
    - Study participant has the presence of active suicidal ideation, or positive suicide behavior using the "Screening" version of the electronic
    Columbia Suicide Severity Rating Scale (eC-SSRS)
    - Presence of moderately severe major depression or severe major
    - Subject has a history of chronic alcohol or drug abuse within 6 months
    prior to Screening
    E.5 End points
    E.5.1Primary end point(s)
    1. Percentage of participants achieving clinical response as measured by
    Hidradenitis Suppurativa Clinical Response 75 (HiSCR75) at Week 16
    2. Absolute change from Baseline in Dermatology Life Quality Index
    (DLQI) Total Score at Week 16
    3. Absolute change from Baseline in Skin Pain score at Week 16
    4. Percentage of participants achieving Skin Pain response at Week 16
    5. Percentage of participants with treatment-emergent adverse events
    (TEAEs) during the study
    6. Percentage of participants with serious treatment-emergent adverse
    events during the study
    7. Percentage of participants with treatment-emergent adverse events
    (TEAEs) leading to withdrawal from the stud
    E.5.1.1Timepoint(s) of evaluation of this end point
    Week 16
    E.5.2Secondary end point(s)
    1. Percentage of participants achieving clinical response as measured by
    Hidradenitis Suppurativa Clinical Response 75 (HiSCR75) at Week 16
    2. Percentage of participants with Flare by Week 16
    3. Absolute change from Baseline in Dermatology Life Quality Index
    (DLQI) Total Score at Week 16
    4. Absolute change from Baseline in Skin Pain score at Week 16
    5. Percentage of participants achieving Skin Pain response at Week 16
    6. Percentage of participants with treatment-emergent adverse events
    (TEAEs) during the study
    7. Percentage of participants with serious treatment-emergent adverse
    events during the study
    8. Percentage of participants with treatment-emergent adverse events
    (TEAEs) leading to withdrawal from the study
    E.5.2.1Timepoint(s) of evaluation of this end point
    1: Week 16
    2, 3, 4: From Baseline (Day 1) to Week 16
    5, 6, 7: From Baseline (Day 1) until Safety Follow-Up (up to Week 71)
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic Yes
    E.6.11Pharmacogenomic Yes
    E.6.12Pharmacoeconomic Yes
    E.6.13Others Yes
    E.6.13.1Other scope of the trial description
    Tolerability, Immunogenicity
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E. trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial4
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned3
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA55
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years1
    E.8.9.1In the Member State concerned months9
    E.8.9.1In the Member State concerned days1
    E.8.9.2In all countries concerned by the trial years3
    E.8.9.2In all countries concerned by the trial months0
    E.8.9.2In all countries concerned by the trial days11
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 485
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 5
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state30
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 253
    F.4.2.2In the whole clinical trial 490
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Eligible subjects will be allowed to enroll in an Open-Label Extension
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2020-05-15
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2020-09-17
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2023-02-19
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands